



IFW  
13

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of

Docket No: Q95272

Kazuhito IKEDA, et al.

Appln. No.: 10/581,663

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: June 5, 2006

For: THERAPEUTIC OR PREVENTIVE AGENTS FOR ISCHEMIC NEUROPATHY

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. Y. Luo et al., "Collapsin: A Protein in Brain That Includes the Collapse and Paralysis of Neuronal Growth Cones", Cell, Vol. 75, October 22, 1993, pp. 217-227.
2. A. Kolodkin et al., "The *semaphoring* Genes Encode a Family of Transmembrane and Secreted Growth Cone Guidance Molecules", Cell. Vol. 75, December 31, 1993, pp. 1389-1399.
3. A. Shirvan et al., "Anti-semaphorin 3A Antibodies Rescue Retinal Ganglion Cells from Cell Death following Optic Nerve Axotomy", The Journal of Biological Chemistry, Vol. 277, No. 51, Issue of December 20, 2002, pp. 49799-49807.

Kazuhiro IKEDA, et al.  
U.S. Appln. No.: 10/581,663  
INFORMATION DISCLOSURE STATEMENT

4. A. Solomon et al., "Up-regulation of semaphoring expression in retina glaucomatous rabbits", Graefe's Archive for Clinical and Experimental Ophthalmolgy, (2003), 241, pp. 673-681.
5. H. Fujita et al., "Expression of neuropilin-1, neuropilin-2 and semaphoring 3A Mrna in the rat brain after middle cerebral artery occlusion", Brain Research 914, (2001), pp. 1-14.
6. U.S. Patent No. 2003/0166711 A1 issued September 4, 2003.
7. U.S. Patent No. 2005/0119334 A1 issued June 2, 2005.
8. WO 03/062440, published July 31, 2003 with Abstract.
9. WO 92/16517, published October 1, 1992 corresponds to JP 6-506202, listed on the PTO/SB/08 A&B filed June 5, 2006.
10. G. Gammon et al., "A fungal metabolite which inhibits the interaction of CD4 with major histocompatibility complex-encoded class II molecules", European Journal of Immunology, 24, (1994), pp. 991-998 previously listed on the PTO/SB/08 A&B filed June 5, 2006.
11. K. Kikuchi et al., "*In Vitro* and *Vivo* Characterization of a Novel Semaphorin 3A Inhibitor, SM-216289 or Xanthofulvin", The Journal of Biological Chemistry, Vol. 278, No. 44, Issue of October 31, 2003, pp. 42985-42991, previously listed on the PTO/SB/08 A&B filed on June 5, 2006.
12. T. Nakayama et al., "Role of Cdk5 and Tau Phosphorylation in Heterotrimeric G Protein-Mediated Retinal Growth Cone Collapse", Journal of Neurobiology, 41, (1999), pp. 326-339, previously listed on the PTO/SB/08 A&B filed June 5, 2006.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for .

Kazuhiro IKEDA, et al.  
U.S. Appl. No.: 10/581,663  
INFORMATION DISCLOSURE STATEMENT

continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.


The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

  
John T. Callahan  
Registration No. 32,607

Date: July 28, 2006

Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/581,663
Confirmation Number	Unknown
Filing Date	June 5, 2006
First Named Inventor	Kazuhito IKEDA
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q95272

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 2003/0166711	A1	09/04/2003	Kimura et al.
		US 2005/0119334	A1	06/02/2005	Kumagai et al
		US			
		US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		WO	03/062440		07/31/2003	Sumitomo Pharm Co., Ltd	Abstract

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Y. Luo et al., "Collapsin: A Protein in Brain That Includes the Collapse and Paralysis of Neuronal Growth Cones", Cell, Vol. 75, October 22, 1993, pp. 217-227.	
		A. Kolodkin et al., "The <i>semaphoring</i> Genes Encode a Family of Transmembrane and Secreted Growth Cone Guidance Molecules", Cell. Vol. 75, December 31, 1993, pp. 1389-1399.	
		A. Shirvan et al., "Anti-semaphorin 3A Antibodies Rescue Retinal Ganglion Cells from Cell Death following Optic Nerve Axotomy", The Journal of Biological Chemistry, Vol. 277, No. 51, Issue of December 20, 2002, pp. 49799-49807.	
		A. Solomon et al., "Up-regulation of semaphoring expression in retina glaucomatous rabbits", Graefe's Archive for Clinical and Experimental Ophthalmology, (2003), 241, pp. 673-681.	
		H. Fujita et al., "Expression of neuropilin-1, neuropilin-2 and semaphoring 3A Mrna in the rat brain after middle cerebral artery occlusion", Brain Research 914, (2001), pp. 1-14.	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.